These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9386214)

  • 41. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy.
    Henriksson L; Stjernquist M; Boquist L; Alander U; Selinus I
    Am J Obstet Gynecol; 1994 Sep; 171(3):624-32. PubMed ID: 8092207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.
    Nappi RE; Kokot-Kierepa M
    Climacteric; 2012 Feb; 15(1):36-44. PubMed ID: 22168244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urogenital aging--a hidden problem.
    Samsioe G
    Am J Obstet Gynecol; 1998 May; 178(5):S245-9. PubMed ID: 9609599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
    Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
    Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.
    Biglia N; Peano E; Sgandurra P; Moggio G; Panuccio E; Migliardi M; Ravarino N; Ponzone R; Sismondi P
    Gynecol Endocrinol; 2010 Jun; 26(6):404-12. PubMed ID: 20196634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of vaginal estrogen in Danish women: a nationwide cross-sectional study.
    Meaidi A; Goukasian I; Lidegaard O
    Acta Obstet Gynecol Scand; 2016 Mar; 95(3):280-4. PubMed ID: 26646469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction.
    Santoro N; Worsley R; Miller KK; Parish SJ; Davis SR
    J Sex Med; 2016 Mar; 13(3):305-16. PubMed ID: 26944462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?
    Del Pup L; Di Francia R; Cavaliere C; Facchini G; Giorda G; De Paoli P; Berretta M
    Anticancer Drugs; 2013 Nov; 24(10):989-98. PubMed ID: 24080714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaginal ring an HT alternative.
    Cothran MM; Engberg S
    Nurse Pract; 2004 Jul; 29(7):54-5. PubMed ID: 15238860
    [No Abstract]   [Full Text] [Related]  

  • 51. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy.
    Ulrich LS; Naessen T; Elia D; Goldstein JA; Eugster-Hausmann M;
    Climacteric; 2010 Jun; 13(3):228-37. PubMed ID: 20423243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The urogenital system and the menopause.
    Calleja-Agius J; Brincat MP
    Climacteric; 2015; 18 Suppl 1():18-22. PubMed ID: 26366796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy.
    Ayton RA; Darling GM; Murkies AL; Farrell EA; Weisberg E; Selinus I; Fraser ID
    Br J Obstet Gynaecol; 1996 Apr; 103(4):351-8. PubMed ID: 8605133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004.
    Society of Obstetricians and Gynaecologists of Canada
    Int J Gynaecol Obstet; 2005 Feb; 88(2):222-8. PubMed ID: 15779109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
    Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
    Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy.
    Chuery AC; Speck NM; de Moura KF; Belfort PN; Sakano C; Ribalta JC
    Clin Exp Obstet Gynecol; 2011; 38(2):143-5. PubMed ID: 21793275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaginal administration of low-dose oestradiol--effects on the endometrium and vaginal cytology.
    Mattsson LA; Cullberg G; Eriksson O; Knutsson F
    Maturitas; 1989 Sep; 11(3):217-22. PubMed ID: 2593865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect and safety of 17 beta-estradiol vaginal tablet in postmenopausal women with urogenital symptoms.
    Manonai J; Theppisai U; Chittacharoen A
    J Med Assoc Thai; 2001 Jul; 84(7):1015-20. PubMed ID: 11759960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vulvovaginal complaints.
    Mehta A; Bachmann G
    Clin Obstet Gynecol; 2008 Sep; 51(3):549-55. PubMed ID: 18677149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.